JONATHAN JAVITT, M.D., M.P.H.
Chief Executive Officer
Dr. Javitt has played leadership roles in seven successful healthcare IT and biopharma startups with public exits. He has additionally led drug-development engagements for Merck, Allergan, Pharmacia, Novartis, and Pfizer. He was appointed to healthcare leadership roles under Presidents Reagan, George H.W. Bush, Clinton, and George W. Bush. In the latter role he was commissioned to lead the White House policy for universal adoption of Health IT and establishment of the Office of the National Coordinator. He is a graduate of Princeton University, Cornell University Medical College, Harvard School of Public Health, the Wills Eye Hospital, and Johns Hopkins Medical School. Dr. Javitt has published more than 200 scientific works in the areas of health outcomes and pharmacoeconomics that have been cited by more than 16,000 people.
RICHARD C. SIEGEL, PH.D.
Executive Vice President of Drug Development and Manufacture
Dr. Siegel brings extensive expertise in both technical and strategic aspects of early and late stage drug development. His experience includes process development and manufacture of small molecule drugs, monoclonal antibodies, therapeutic proteins and conjugates, peptides, cellular products and oligonucleotides. During his career, Dr. Siegel has held a number of high-level drug development and manufacturer positions within the Johnson & Johnson family of companies. These include Vice President of R&D and Global Head of Portfolio Management at Janssen Research and Development.
PHILIP T. LAVIN, PH.D.
Dr. Lavin is a highly-respected biostatistician with more than 30 years of experience supporting the design and analysis of clinical trials. Previously, he was a member of the biostatistics faculty at the Harvard School of Public Health and a member of the Department of Surgery at Harvard Medical School where he was affiliated for over 25 years. He co-founded Boston Biostatistics in 1983, a company now known as Aptiv Solutions. During his career, Dr. Lavin has served as lead biostatistician for 50 FDA approvals, including 38 PMAs, more to date than any other biostatistician. He has also served as a Special Government Employee for 30 years where he has advised FDA on complex statistical and policy issues.
ROBERT BESTHOF, M.I.M.
Chief Commercial & Patient Officer
Mr. Besthof is a global biopharmaceutical executive with a 25+year career covering global pipeline & country operational marketing & sales roles. He has managed numerous specialty diseases areas, including small as well as billion dollar brands in Ophthalmology, Neuroscience, Pain, Pulmonary Vascular Disease, etc. His teams have played key roles in translating new science into investable commercial paths, reshaping markets, launching breakthrough products, and closing numerous licensing deals. Mr. Besthof has worked for Eli Lilly, Wyeth, and most recently Pfizer, as Vice President Commercial Development Neuroscience & Pain. Earlier in his career he worked for Deutsche Bank and for various consulting firms. He holds a B.A. from Case Western Reserve University and a Masters in Int’l Management from the Thunderbird School of Global Management.
ROBERT RISINGER, M.D.
Vice President of Clinical Development
Dr Risinger trained in psychiatry at Emory University completing psychopharmacology and imaging fellowships at NIMH. He then served in the US Air Force becoming Director of Inpatient Psychiatry at Wilford Hall in San Antonio.
He has over 20 years of clinical and academic experience in directing tertiary refractory mood disorders clinics using psychotherapeutic, pharmacologic, ECT and implantable medical devices to address PTSD, Bipolar disorder, substance abuse and other neuropsychiatric conditions.
Interested in serving a greater clinical population through pharmaceutical development, he was medical director at Janssen, Bristol-Myers Squibb, and Alkermes. He has lead successful Ph 1-4 development from First-In-Human through NDA/sNDA approvals of compounds for psychosis, depression, anxiety, chronic pain and Alzheimer’s.
Regulatory & Patient Advocacy Adviser
Mr. Pines previously served as Associate Commissioner of the US Food and Drug Administration.